Stop Canceling Surgery for Esophageal Cancer: An Analysis of Treatment Related Mortality in 60 000 Patients
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Brian Housman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophagectomy, Adenocarcinoma, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background and Methods Surgical esophagectomy is falsely regarded as contributing little survival in resectable, early‐stage disease in favor of nonsurgical treatment with definitive chemoradiation (dCR). We examine surgery in treatment by evaluating large‐scale trends in mortality. The SEER database was queried for esophageal cancer patients from 2004 to 2020. Total of 59 754; 19 806 squamous and 34 484 adenocarcinoma. The primary outcome was the hazard ratio for overall survival defined as time from diagnosis‐to‐death. Differences between patients were assessed using χ 2 tests for categorical variables and t ‐tests for continuous variables. Difference in survival by histology was assessed using Kaplan‐Meier curves and Cox Proportional Hazards models.
Results
A total of 47 170 (78.9%) did not undergo surgery and 12 584 (21.1%) received surgery. The hazard ratio for patients undergoing dCR for SCC was 1.929. The hazard ratio for treatment with dCR compared to chemoradiation‐followed‐by‐surgery (CRS) was 2.151 and for adenocarcinoma 2.386. Further analyses highlight groups under similar clinical conditions; including multivariate analysis, T‐Stage, overall stage, surgical era, and surgery refusal. In every category, the risk of mortality was higher in dCR compared to CRS.
Conclusions
Surgery combined with chemoradiation, and/or surgery alone, confers a significant survival benefit over dCR in resectable patients.
Discussion
Surgery should be considered early in medically fit patients with operable disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Karyn A Goodman, Emanuela Taioli, Raja Flores
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Housman, B., Gulati, S., Kulshrestha, A., Untalan, M., Ivic-Pavlicic, T., Tuminello, S., Goodman, K. A., Taioli, E., & Flores, R. (2025). Stop Canceling Surgery for Esophageal Cancer: An Analysis of Treatment Related Mortality in 60 000 Patients. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70085
Vancouver
Housman B, Gulati S, Kulshrestha A, Untalan M, Ivic-Pavlicic T, Tuminello S, et al. Stop Canceling Surgery for Esophageal Cancer: An Analysis of Treatment Related Mortality in 60 000 Patients. Journal of Surgical Oncology. 2025. doi:10.1002/jso.70085
BibTeX
@article{Housman2025,
author = {Housman, Brian and Gulati, Shubham and Kulshrestha, Ashwin and Untalan, Matthew and Ivic-Pavlicic, Tara and Tuminello, Stephanie and Goodman, Karyn A and Taioli, Emanuela and Flores, Raja},
title = {Stop Canceling Surgery for Esophageal Cancer: An Analysis of Treatment Related Mortality in 60 000 Patients},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.70085}
}
EUVIMED